ATHENA: A Phase 3, Open-Label Study Of The Safety And Effectiveness Of Oliceridine (TRV130), A G-Protein Selective Agonist At The µ-Opioid Receptor, In Patients With Moderate To Severe Acute Pain Requiring Parenteral Opioid Therapy

BACKGROUND: Pain management with conventional opioids can be challenging due to dose-limiting adverse events (AEs), some of which may be related to the simultaneous activation of β-arrestin (a signaling pathway associated with opioid-related AEs) and G-protein pathways. The investigational analgesic...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Pain Res
Main Authors: Bergese, Sergio D, Brzezinski, Marek, Hammer, Gregory B, Beard, Timothy L, Pan, Peter H, Mace, Sharon E, Berkowitz, Richard D, Cochrane, Kristina, Wase, Linda, Minkowitz, Harold S, Habib, Ashraf S
Formato: Artigo
Idioma:Inglês
Publicado em: Dove 2019
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6861532/
https://ncbi.nlm.nih.gov/pubmed/31814753
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JPR.S217563
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados